These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 380805)

  • 1. Combination of adriamycin and cyclophosphamide in the treatment of metastatic prostatic carcinoma: a phase II study.
    Izbicki RM; Amer MH; Al-Sarraf M
    Cancer Treat Rep; 1979 Jun; 63(6):999-1001. PubMed ID: 380805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemotherapy for stage III-IV epithelial ovarian cancer with cis-dichlorodiammineplatinum(II), adriamycin, and cyclophosphamide: a preliminary report.
    Ehrlich CE; Einhorn L; Williams SD; Morgan J
    Cancer Treat Rep; 1979 Feb; 63(2):281-8. PubMed ID: 376134
    [No Abstract]   [Full Text] [Related]  

  • 3. Oral estramustine and cyclophosphamide in patients with metastatic hormone refractory prostate carcinoma: a phase II study.
    Bracarda S; Tonato M; Rosi P; De Angelis V; Mearini E; Cesaroni S; Fornetti P; Porena M
    Cancer; 2000 Mar; 88(6):1438-44. PubMed ID: 10717628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Combination chemo-endocrine therapy of metastatic and stage IV breast cancer with cyclophosphamide, adriamycin, prednisolone and tamoxifen (CAPT)--with special reference to management of brain and liver metastasis].
    Nakamura Y; Kawaguchi M; Hata A; Watanabe H; Ueki Y; Oribe T; Koba F; Takamuku K
    Gan To Kagaku Ryoho; 1989 Feb; 16(2):243-50. PubMed ID: 2919892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer.
    Dhingra K; Frye D; Newman RA; Walters R; Theriault R; Fraschini G; Smith T; Buzdar A; Hortobagyi GN
    Clin Cancer Res; 1995 Jul; 1(7):691-7. PubMed ID: 9816034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized trial of combination chemotherapy in hormone-resistant metastatic prostate carcinoma.
    Page JP; Levi JA; Woods RL; Tattersall MN; Fox RM; Coates AS
    Cancer Treat Rep; 1985 Jan; 69(1):105-7. PubMed ID: 3881176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cyclophosphamide, adriamycin and cisplatinum combination chemotherapy for advanced urothelial and prostatic carcinoma].
    Tsukamoto T; Tanoguchi H; Nakazono M; Murai M; Tachibana M; Deguchi N; Baba S; Hata M; Jitsukawa S; Tazaki H
    Gan To Kagaku Ryoho; 1987 Dec; 14(12):3259-64. PubMed ID: 3688891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cisplatin, doxorubicin, cyclophosphamide, and vindesine combination chemotherapy for non-small cell lung cancer.
    Kelsen D; Gralla R; Stoopler M; Casper E; Cheng E; Kosloff C; Golbey R
    Cancer Treat Rep; 1982 Feb; 66(2):247-51. PubMed ID: 7034932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of cyclophosphamide, adriamycin, and cis-dichlorodiammineplatinum (II) by infusion in patients with adenocarcinoma and large cell carcinoma of the lung.
    Eagan RT; Frytak S; Creagan ET; Ingle JN; Kvols LK; Coles DT
    Cancer Treat Rep; 1979; 63(9-10):1589-91. PubMed ID: 227597
    [No Abstract]   [Full Text] [Related]  

  • 10. Adriamycin (NSC-123127) versus 5-fluorouracil (NSC-19893) and cyclophosphamide (NSC-26271) in the treatment of metastatic prostate cancer.
    Eagan RT; Hahn RG; Myers RP
    Cancer Treat Rep; 1976 Jan; 60(1):115-7. PubMed ID: 1000515
    [No Abstract]   [Full Text] [Related]  

  • 11. Controlled prospective trial of combination chemotherapy with cyclophosphamide, adriamycin, and 5-fluorouracil for the treatment of advanced ovarian cancer: a preliminary report.
    Bruckner HW; Pagano M; Falkson G; Creech R; Arseneau JC; Horton J; Brodovsky H; Davis TE; Slayton RW; Greenspan E
    Cancer Treat Rep; 1979 Feb; 63(2):297-9. PubMed ID: 376136
    [No Abstract]   [Full Text] [Related]  

  • 12. Combination chemotherapy with adriamycin (NSC-123127) and cyclophosphamide (NSC-26271) for solid tumors: a phase II trial.
    Lloyd RE; Jones SE; Salmon SE; Durie BG; McMahon LJ
    Cancer Treat Rep; 1976 Jan; 60(1):77-83. PubMed ID: 1000520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclophosphamide (NSC 26271) versus the combination of adriamycin (NSC 123127), 5-fluorouracil (NSC 19893), and cyclophosphamide in the treatment of metastatic prostatic cancer: a randomized trial.
    Chlebowski RT; Hestorff R; Sardoff L; Weiner J; Bateman JR
    Cancer; 1978 Dec; 42(6):2546-52. PubMed ID: 365313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II trial cisplatin, doxorubicin, and cyclophosphamide (CAP) in the treatment of urothelial transitional cell carcinoma.
    Campbell M; Baker LH; Opipari M; Al-Sarraf M
    Cancer Treat Rep; 1981; 65(9-10):897-9. PubMed ID: 7196800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination chemotherapy with cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) in advanced breast carcinoma.
    Dalley DN; Levi JA; Aroney RS
    Med J Aust; 1980 Mar; 1(5):216-8. PubMed ID: 6990214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II trial of adriamycin in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study.
    Thigpen JT; Buchsbaum HJ; Mangan C; Blessing JA
    Cancer Treat Rep; 1979 Jan; 63(1):21-7. PubMed ID: 369691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advanced ovarian carcinoma: a pilot study of cis-dichlorodiammineplatinum(II) in combination with adriamycin and cyclophosphamide in previously untreated patients and as a single agent in previously treated patients.
    Williams CJ; Stevenson KE; Buchanan RB; Whitehouse JM
    Cancer Treat Rep; 1979; 63(11-12):1745-53. PubMed ID: 393378
    [No Abstract]   [Full Text] [Related]  

  • 18. cis-Dichlorodiammineplatinum(II) alone followed by adriamycin plus cyclophosphamide at progression versus cis-dichlorodiammineplatinum(II), adriamycin, and cyclophosphamide in combination for adenocarcinoma of the lung.
    Britell JC; Eagan RT; Ingle JN; Creagen ET; Rubin J; Frytak S
    Cancer Treat Rep; 1978 Aug; 62(8):1207-10. PubMed ID: 688256
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination chemotherapy for ovarian carcinoma with cyclophosphamide, adriamycin, and cis-dichlorodiammineplatinum(II) after failure of initial chemotherapy.
    Bruckner HW; Ratner LH; Cohen CJ; Wallach R; Kabakow B; Greenspan EM; Holland JF
    Cancer Treat Rep; 1978 Jul; 62(7):1021-3. PubMed ID: 688244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CAP (cyclophosphamide, doxorubicin, and cisplatin) regimen in adrenal cortical carcinoma.
    van Slooten H; van Oosterom AT
    Cancer Treat Rep; 1983 Apr; 67(4):377-9. PubMed ID: 6687835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.